BRD4 and pancreatic ductal adenocarcinoma: The dual BRD4 and CBP/p300 bromodomain co-inhibitor XP-524 exhibits higher potency and superior tumoricidal activity than the BRD4 inhibitor JQ-1, and shows anticancer efficacy comparable to combination therapy with high-dose JQ-1 and the CBP/p300 inhibitor SGC-CBP30 in pancreatic ductal adenocarcinoma cells [62].